# Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Study · id `cardio:ct-nct01531374` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01531374](<https://clinicaltrials.gov/study/NCT01531374>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01531374

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2777 participants.

## Technical summary

Registry record NCT01531374. Non-randomized; no masking; primary purpose treatment. Start 2012-02-21 (actual); primary completion 2015-11 (actual). Results posted on 2017-07-18.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2777 participants (enrolled count; ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Started: 2012-02-21 (actual) (ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Primary completion: 2015-11 (actual) (ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Completion: 2019-11-18 (actual) (ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Results first posted: 2017-07-18 (ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01531374, source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01531374-2022-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
- Condition: Severe Aortic Stenosis
- Intervention (Device): Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
- Lead sponsor: Medtronic Cardiovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: 913ac1ee4de491f74306e5800f5a0b718cfc194589b5849eaf3b46d1ed3677f4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
